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Abstract
Purpose: Vemurafenib is a potent inhibitor of V600 mutant BRAF with significant impact on progression-free and overall
survival in advanced melanoma. Cutaneous side effects are frequent. This single-center observational study investigates
clinical and histological features of these class-specific cutaneous adverse reactions.
Patients and Methods: Patients were all treated with Vemurafenib 960 mg b.i.d. within local ethic committees approved
clinical trials. All skin reactions were collected and documented prospectively. Cutaneous reactions were classified by
reaction pattern as phototoxic and inflammatory, hair and nail changes, keratinocytic proliferations and melanocytic
disorders.
Results: Vemurafenib was well tolerated, only in two patients the dose had to be reduced to 720 mg due to arthralgia. 26/
28 patients (93%) experienced cutaneous side effects. Observed side effects included UVA dependent photosensitivity
(n = 16), maculopapular exanthema (n = 14), pruritus (n = 8), folliculitis (n = 5), burning feet (n = 3), hair thinning (mild
alopecia) (n = 8), curly hair (n = 2) and nail changes (n = 2). Keratosis pilaris and acanthopapilloma were common skin
reactions (n = 12/n = 13), as well as plantar hyperkeratosis (n = 4), keratoacanthoma (n = 5) and invasive squamous cell
carcinoma (n = 4). One patient developed a second primary melanoma after more than 4 months of therapy (BRAF and RAS
wild type).
Conclusion: Vemurafenib has a broad and peculiar cutaneous side effect profile involving epidermis and adnexa
overlapping with the cutaneous manifestations of genetic diseases characterized by activating germ line mutations of RAS
(RASopathy). They must be distinguished from allergic drug reaction. Regular skin examination and management by
experienced dermatologists as well as continuous prophylactic photo protection including an UVA optimized sun screen is
mandatory.
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Introduction
A variety of unspecific toxicities of cytotoxic agents which
emerge in skin, mucosa and adnexa are common. New targeted
agents cause class-specific cutaneous side effects.[1–6].
An activating BRAF mutation is detected in 40% of melanomas,
the most common being BRAF V600 E mutation. Several potent
inhibitors of the oncogenic BRAF kinase have been developed and
tested in clinical trials. [7,8] The dose-limiting side effects of these
inhibitors include arthralgia, nausea, photosensitivity, fatigue,
pruritus and palmar–plantar dysesthesia. In addition, multiple
other cutaneous side effects are observed including keratoacantho-
mas, invasive squamous cell carcinomas and melanomas.[9–12].
Vemurafenib (formerly called PLX4032, RG7204, RO5185426)
was the first selective BRAF inhibitor to be developed in a clinical
setting. This potent inhibitor, orally available, has shown significant
impact on both progression-free and overall survival throughout
phase I-III clinical trials (BRIM-1, BRIM-2, BRIM-3). [9,13,14]
Vemurafenib (Zelboraf) has been approved by the FDA, the EMA
and in Switzerland. So far, attention regarding the cutaneous side
effects of this drug has been mainly devoted to keratinocytic
neoplasias such as keratoacanthomas and squamous cell carcino-
mas, which were seen in 18 to 24% of patients. [9,13] There is some
evidence that the use of a mutation specific BRAF inhibitor leads to
a paradoxical activation of the MAPK pathway in cells wild type for
BRAF, resulting in cutaneous neoplasias in case of mutations
upstream such as RAS. [15] However, far more cutaneous side
effects are being observed under treatment and have an important
impact on drug tolerance as well as on quality of life.
We investigated the incidence, time point, duration, outcome,
clinical presentation and histopathology of this broad spectrum of
new class-specific cutaneous side effects induced by Vemurafenib
in a cohort of 28 patients undergoing treatment with this drug in
clinical trials.
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Figure 1. Clinical presentation of the maculopapular rash after 2 weeks of therapy.
doi:10.1371/journal.pone.0058721.g001
Figure 2. Histology of the maculopapular rash demonstrates a lichenoid lymphohistiocytic infiltrate with interface changes,
hematoxylin and eosin stain.
doi:10.1371/journal.pone.0058721.g002
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Patients and Methods
Patient Selection
A total of 28 patients (15 females, 13 males, age 24–77 years)
with metastatic melanoma attending the Dermatology Depart-
ment of the University Hospital of Zurich and undergoing clinical
trials with Vemurafenib during June 2010 until June 2011 formed
the study cohort. Written informed consent for inclusion into the
trials was obtained from study participants after approval from
local ethics committees (Kantonale Ethikkomission Zu¨rich and
Swissmedic, see also clinical trials below) as well as the consent to
store their information in the hospital database and to use it for
Figure 3. Immunihistological staining for Ki67 in maculopapular rash under treatment with vemurafenib shows increased staining
in comparison to normal skin (normal skin not shown).
doi:10.1371/journal.pone.0058721.g003
Figure 4. Plantar hyperkeratosis developed after 4 weeks of therapy.
doi:10.1371/journal.pone.0058721.g004
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research, including publication of photographs (as outlined in the
PLoS consent form), (Kantonale Ethikkomission Zu¨rich Biobank/
Sammlung von Tumorgewebe, KEK-ZH-Nr. 647).
Data on treatment and all occurring side effects were collected
prospectively. Cutaneous reactions were classified by reaction
pattern as inflammatory diseases, hair and nail changes,
keratinocytic proliferations and melanocytic disorders and prolif-
erations. The appearance of lesions was noted according to
treatment duration and was subdivided into three different time
intervals of early, intermediate, and late therapy phase (less than 3
weeks, 3 to 6 weeks and more than 6 weeks after therapy start)
(Figure 11, 12). A total of 51 Biopsies were collected during the
observation period. The biopsies where formalin-fixed, paraffin-
embedded and subsequently stained with hematoxylin and eosin
or immunochemically stained to detect Ki-67, using MIB-1-
Antibody (Dako, Glostrup, Denmark).
Clinical Trials
Eligible patients with BRAF-mutant melanoma were enrolled in
one of the following clinical trials of Vemurafenib (RO5185426,
former PLX 4032): Mass balance trial, a Phase I, open-label,
excretion balance, pharmacokinetic and metabolism study for a
single oral dose of 14C-labeled Vemurafenib in previously treated
Figure 5. Acanthopapilloma with marked hyperkeratosis and acanthosis, hematoxylin and eosin stain.
doi:10.1371/journal.pone.0058721.g005
Figure 6. Clinical picture of the kerathoacanthoma, appeared
after 5 weeks of treatment.
doi:10.1371/journal.pone.0058721.g006
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and untreated patients with metastatic melanoma (Registry:
NCT01164891, KEK-ZH-Nr. 2010-0109/5, Swissmedic
2010DR1116); BRIM-3 trial, a randomized, open-label, con-
trolled, multicenter, phase III study in previously untreated
patients with unresectable stage IIIC or stage IV melanoma with
V600E BRAF mutation receiving Vemurafenib or Dacarbazine
(Registry: NCT01006980, KEK-ZH-Nr. 2009-0134/5, Swissme-
dic 2010DR3078); Roche MO25653 trial, an open-label pilot
study of Vemurafenib in previously treated metastatic melanoma
patients with brain metastases (Registry: NCT01253564, KEK-
ZH-Nr. 2010-0492/0, Swissmedic 2010DR2228) or Roche
MO25515 trial, an open-label, multicenter expanded access study
of Vemurafenib in patients with metastatic melanoma (Registry:
EudraCT Number: 2010-023526-21, KEK-ZH-Nr. 2010-0535/0,
Swissmedic 2011DR3030). [13,16] BRAF testing was performed
with the cobasH 4800 BRAF V600 Mutation Test.
All patients were treated with 960 mg b.i.d.; in two patients dose
reduction to 720 mg b.i.d was necessary due to side effects, both
suffering from arthralgia. Treatment duration lasted from 2 to 12
months. Treatment regimen was stopped when patients experi-
enced progressive disease. No treatment discontinuation was
necessary because of side effects.
In 5 of the patients MED (Minimal Erythema Dose) was
determined to objectify photosensitivity under Vemurafenib using
UV irradiation devices (UVB: emission spectrum from 285 nm to
350 nm (peak at 310–315 nm), UVA 330 nm to 450 nm (peak at
390–410 nm) (Waldmann Lichttechnik, Villingen-Schwenningen,
Germany) 10 minutes and 24 hours after irradiation.
Results
26 patients out of 28 (93%) experienced cutaneous side effects
upon drug administration. The emerging adverse reactions were
classified by reaction patterns and time of appearance as follows:
Inflammatory Disorders
Photosensitivity reaction. Photosensitivity was observed in
16/28 (57%) patients. In most cases it presented during early
phase of therapy. Testing in five patients showed a normal
minimal erythema dose (MED) for UVB (range of 0.008 to 0.099
J/cm2) in all patients, but a clearly reduced MED for UVA (range
10–49 J/cm2) after 10 minutes and 24 hours. In addition, three
patients reported burning and pain during UVA exposure. The
UV irradiated fields showed a bold erythema including a
pronounced edema. [17].
Figure 7. Invagination of keratinizing, squamous epithelium with central keratin-filled crater characterizing a keratoacanthoma,
hematoxylin and eosin stain.
doi:10.1371/journal.pone.0058721.g007
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Maculopapular exanthema. A maculopapular exanthema
was observed 19 times in 14 of 28 patients (50%). The clinical
picture showed a disseminated pale erythematous maculopapular
rash on the trunk and extremities, less frequent on the face
(Figure 1). The majority of cases presented during early and
intermediate treatment phase without pruritus and were self-
limiting mostly within 4 to 6 weeks. Histologically, these were
mostly characterized by vacuolar alteration of the epidermal-
dermal junction with a mild perivascular and lichenoid lympho-
histiocytic infiltrate with few admixed eosinophils (Figure 2). Mild
inflammatory infiltrates around adnexal structures such as hair
follicles, sebaceous and eccrine glands were seen in most patients.
Interestingly, a lichenoid spongiotic reaction pattern with involve-
ment of adnexal structures was found in one case, whereas in
another case a focal granulomatous inflammatory infiltrate and
marked syringotropism was noted. Direct immunoflourescence for
fibrinogen, C3, IgG, IgA and IgM was negative in all 3 performed
biopsies. In comparison to age and site matched healthy skin,
immunohistological staining with Ki-67 showed an increasing of
the Ki-67-immunoreactivity in the basal layer of the keratinocytes
and in the suprabasal and hair follicle keratinocytes. Normal skin
shows only a few scattered Ki-67 positive cells in the basal layer
(Figure 3). Because of the small sample size no statistical analysis
where performed.
Follicular rash. Follicular rash or scattered pustules ap-
peared in 5/28 (18%) patients, mostly during intermediate
treatment phase.
In two biopsies, a perifollicular and follicular infiltrate of
lymphocytes and neutrophils was notable, accompanied by
discrete perifollicular fibrosis.
Pruritus. Pruritus sine rash was experienced 9 times in a total
of 8/28 (29%) patients during the early treatment phase. Pruritus
was self-limiting in most cases.
Infectious diseases. Infection was an uncommon problem.
One patient experienced a disseminated herpes zoster in the late
treatment phase under treatment with high dose corticosteroids
because of brain metastases. A second patient developed anal
herpes simplex in very early treatment stage. Two other patients
showed furuncles after more than 6 weeks of treatment.
One patient presented with an acute, diffuse erythema of the leg
after 3 weeks on treatment and was diagnosed with cellulitis,
responding well to antibiotic treatment. Histologically a perivas-
cular inflammatory infiltrate with numerous neutrophils through-
out the whole dermis could be detected. No eosinophils were seen.
Overall we do not think that these infectious episodes are
specifically related to the Vemurafenib treatment.
Figure 8. Section of skin with desmoplastic squamous cell carcinoma, hematoxylin and eosin stain.
doi:10.1371/journal.pone.0058721.g008
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Hair and Nail Changes
Hair thinning and diffuse alopecia occurred in 8/28 (29%)
patients. This side effect was observed mostly starting from the
third treatment week and continuing thereafter. There was no
complete hair loss.
After more than 6 weeks of treatment, 2/28 (7%) patients
reported curling of the hair after experiencing hair thinning; the
latter was less pronounced later during course of treatment.
Crumbly nails and nail color change was encountered in 2/28
(7%) patients after two weeks and 6 weeks of treatment,
respectively.
Keratinocytic Proliferations
Keratosis pilaris. Disseminated small hyperkeratotic follic-
ular papules were noted in 12/28 (43%) patients. This occurred
often on the face, proximal upper or lower extremities and was
observed more frequently at early treatment time points).
Plantar hyperkeratosis. Plantar hyperkeratosis was detect-
ed in 4/28 (14%) patients, occurring in areas under physical
pressure. All patients but one were more than 6 weeks under
treatment with BRAF inhibitor. Additionally, two of these patients
described a painful sensation on the hyperkeratotic areas. There
was no palmar hyperkeratosis (Figure 4).
One patient reported a painful, burning sensation on the soles
with a diffuse erythema, but without hyperkeratosis.
Acanthopapilloma. Acanthopapillomas (benign acanthotic
lesion without signs of malignancy) were a frequently observed
dermatologic side effect. 13 out of 28 patients (46%) developed a
total of 30 hyperkeratotic papules on the head, neck and trunk,
corresponding to acanthopapillomas in the course of therapy. As
shown in Figure 12, this side effect occurs at later time points
during therapy. Histological evaluation of 30 biopsies of these
lesions revealed marked hyperkeratosis and acanthosis with
hypergranulosis, koilocytes, mitosis and arborization of the
peripheral rete ridges suggesting viral association (Figure 5).
Squamous cell carcinoma and
keratoacanthoma. Squamous cell carcinomas of keratoacan-
thoma type were observed in 5/28 (18%) patients in the late phase
of treatment.
Histological features in 5 biopsies were an invagination of
keratinizing, well-differentiated squamous epithelium with central
keratin-filled crater and symmetrical lipping at the edges of the
lesion. 2 cases were diagnosed as keratoacanthoma centrifugum
marginatum (Figure 6, 7).
Seven invasive squamous cell carcinomas were observed in 4/28
(14%) patients with photodamaged skin, some with multiple
lesions, mostly in the intermediate phase of therapy).
Histologically, infiltrative growing squamous epithelial cells,
mostly well differentiated, could be detected. However, in few
cases these tumors were less well differentiated and required
Figure 9. Dermoscopic picture of the melanoma, appeared after more than 4 months of therapy with vemurafenib.
doi:10.1371/journal.pone.0058721.g009
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several surgical procedures to achieve complete resection. There
was one squamous cell carcinoma with an aggressive desmoplastic
growth pattern (Figure 8).
Furthermore, the development of Bowen’s Disease, bowenoid
squamous cell carcinoma and basal cell carcinoma was observed in
single cases as well as a warty dyskerathoma, showing acantholysis
and dyskeratosis.
Melanocytic Disorders and Proliferations
Melanoma. One patient developed a new asymmetrical
brownish macule with a sharp border on the capillitium after
more than 4 months of therapy. Suspecting a new primary
melanoma, the lesion was excised (Figure 9).
Histology revealed an asymmetric, poorly cicrcumscribed,
melanocytic proliferation with atypical melanocytes at the
junctional and suprabasal layers as well as in the follicular
epithelia. The dermal component of the neoplasm showed no signs
of maturation. Peritumoral inflammatory infiltrate was noted.
Superficial spreading melanoma, Breslow thickness 0.45 mm,
Clark-level III, without ulceration, was diagnosed (Figure 10).
There was no evidence of BRAF or NRAS- mutation in this lesion
(tested by cobasH 4800 BRAF V600 Mutation Test and
polymerase chain reaction sequencing, respectively).
Discussion
The most common adverse events occurring during Vemur-
afenib treatment and impacting on the quality of life are skin
reactions. So far, no detailed investigation of cutaneous side effects
of Vemurafenib accompanied by biopsies has been reported. [10]
We analyzed cutaneous side effects under BRAF inhibitors in 28
consecutive patients, focusing on reaction patterns and time of
appearance. An attempt to classify these cutaneous adverse events
was made in order to facilitate clinical follow-up and diagnosis in a
clinical setting.
There was a peculiar sequence of skin reactions with
maculopapular exanthema sparing the face in the first four weeks,
photosensitivity that occurred in 16 of 28 patients despite the strict
recommendation to use sun screens and pruritus in 8 of 28
patients. The photosensitivity is UVA induced and has significant
effect on the patient’s quality of life.
Cutaneous reaction 3–6 weeks after treatment initiation
(Figure 11, 12) included inflammatory diseases like maculopapular
exanthema, folliculitis and others, dystrophic hair- and nail
changes and keratinocytic neoplasms. Late side effects (over 6
weeks on treatment) consisted mainly of keratinocytic prolifera-
Figure 10. Asymmetric not well circumcised melanocytic proliferation revealing a melanoma with a breslow index of 0.45 mm,
hematoxylin and eosin stain.
doi:10.1371/journal.pone.0058721.g010
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tions, especially acanthopapillomas and keratoacanthomas as well
as keratosis pilaris and hair dystrophies.
Alarmingly, second primary melanomas have been found in an
unexpected high frequency [18,19].
The paradox of new malignancies such as keratoacanthoma and
squamous cell carcinoma has attracted intensive research.
Oberholzer et al. have shown that 21% of squamous cell
carcinomas and keratoacanthomas presented activating RAS
mutations. [11] In addition, Su et al. confirmed that mutations
in RAS, particularly HRAS, are frequent in keratoacanthomas
and squamous cell carcinomas in patients treated with Vemur-
afenib. [20] They have elegantly demonstrated that activated RAS
will result in a paradoxical activation of MAPK signaling
accelerating tumor growth in BRAF wild type lesions. This
suggests that RAS activation is the key event for the progression of
keratoacanthomas and squamous cell carcinomas. Homodimer
and heterodimer formation involving all members of the BRAF
family seems to be involved. [21–23].
In case of wild type RAS, an activating signal upstream of RAF
such as a mutated EGF-R might drive keratoacanthoma and
squamous cell carcinoma proliferation. We have found evidence of
a remarkably increased proliferation of keratinocytes shown by
immunohistochemistry during the early maculopapular rash,
which suggest an increased proliferation rate in the epidermis
and follicular structures compared to normal skin.
We argue therefore that other manifestations of the spectrum of
skin eruptions depend on RAS activation and therefore might be
called RASopathic.
The term RASopathy was introduced to classify a group of
syndromes with activating RAS/MAPK germline mutations
including cardiofaciocutaneous syndrome (CFC), Costello syn-
drome (CS), Noonan syndrome and others. [24,25].
These rare genetic syndromes present multisystem disorders
with characteristic coarse facial appearance, intellectual disabili-
ties, tumor predisposition and a spectrum of cutaneous alterations
that overlap with Vemurafenib associated skin lesions. [25].
Besides squamous cell carcinomas and keratoacanthomas, many
patients present benign keratinocytic neoplasias that are acantho-
papillomas or seborrheic keratosis by histology. FGF-R mutations
have been found in seborrheic keratosis to be able to activate the
pathway. [26] Patients with CS and CFC typically present with
acanthopapillomas generally located on the face, especially around
the nose.
Keratosis pilaris, plantar pressure dependent hyperkeratosis and
dystrophic curly hair with slow growth are common in patients
affected by CS or CFC and in Vemurafenib treated patients. The
callus like palmo-plantar hyperkeratosis without significant
inflammation must be carefully distinguished from the palmo-
plantar dysethesia syndrome that is a typical and often a dose
limiting adverse event during VEGF targeting small molecules
such as sunitinib and sorafenib.
Keratosis pilaris, cyst formation and plantar hyperkeratosis
might be increased by a dysregulation of the fine tuning of the
pathway after physiological stimulation. All the three are classical
symptoms of RASopathies.
These cutaneous alterations in addition to squamous cell
carcinoma and keratoacanthoma are also observed during
sorafenib therapy. [3] This paper suggests an induction of
keratinocytic hyperproliferation by sorafenib without signs of
apoptosis resulting in increased epidermal thickness in normal
Figure 11. Appearance of keratinocytic proliferations over time during vemurafenib treatment. Timepoint 1:1–3 weeks; timepoint 2:3–6
weeks; timepoint 3: more than 6 weeks.
doi:10.1371/journal.pone.0058721.g011
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skin. This probably contributes to the clinical presentations of
keratosis pilaris and plantar hyperkeratosis. It appears as the
opposite of the reaction pattern induced by MEK inhibitors. MEK
inhibition results in a suppression of the pathway in keratinocytes
resulting in a stress reaction with up-regulation of p53 and a
release of cytokines attracting inflammatory cells with the clinical
presentation of the typical maculopapular and pustular rash
observed during the use of MEK inhibitors. [1].
The dystrophic hair growth with curly thin hairs often
associated with a change of the hair color is often referred to as
alopecia. However, it is definitely different to the hair loss seen
during chemotherapy. It occurs slowly and complete baldness was
not observed in our patients.
As the number of Vemurafenib-treated patients will increase in
the near future, it is important to understand the cutaneous side
effects of this drug. It is essential to distinguish them from allergic
drug reactions. Further classification will facilitate the develop-
ment of follow-up schedules and clinical management. We propose
to conduct detailed dermatological examinations of the skin every
4 weeks during Vemurafenib therapy. Patients should be well
informed of the expected cutaneous side effects, especially about
the UVA photosensitivity. The use of UVA optimized sunscreens
and UV blocking clothing should be strongly recommended, since
testing and experience show a prophylactic effect. [17] In the
future, topical application of the vitamin D derivate calcipotriol
and/or retinoids appears promising to normalize the epidermal
hyperproliferation. [27,28] Further there are observations of
decreased appearing of inflammatory and neoplastic skin lesions
when BRAF inhibitors like vemurafenib are combined with MEK
Inhibitors. [29] Placebo controlled trials will help to investigate the
benefit of these co-medications.
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